Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers

被引:293
|
作者
Scheuer, L
Kauff, N
Robson, M
Kelly, B
Barakat, R
Satagopan, J
Ellis, N
Hensley, M
Boyd, J
Borgen, P
Norton, L
Offit, K
机构
[1] Mem Sloan Kettering Canc Ctr, Clin Genet Serv, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Breast Canc Med Serv, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dev Chemotherapy Serv, Dept Med, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Surg, Breast & Gynecol Serv, New York, NY 10021 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
关键词
D O I
10.1200/JCO.2002.20.5.1260
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose : To prospectively determine the impact of genetic counseling and testing on risk-reduction strategies and cancer incidence in a cohort of individuals at hereditary risk for breast and ovarian cancer. Patients and Methods: Two hundred fifty-one individuals with BRCA mutations were identified at a single comprehensive cancer center from May 1, 1995, through October 31, 2000. Uniform recommendations regarding screening and preventive surgery were provided in the context of genetic counseling. Patients were followed for a mean of 24.8 months (range, 1.6 to 66.0 months) using standardised questionnaires, chart reviews, and contact with primary physicians. Results: Frequency of cancer surveillance by physical examinations and imaging studies increased after genetic counseling and testing. Twenty-one breast, ovarian, primary peritoneal, or fallopian tube cancers were detected after receipt of genetic test results. Among 29 individuals choosing risk-reducing mastectomy after testing, two were found to have occult intraductal breast cancers. Among 90 individuals who underwent risk-reducing salpingo-oophorectomy, one early-stage ovarian neoplasm and one early-stage fallopion tube neoplasm were found. Radiographic or tumor marker-based screening detected six breast cancers, five of which were stage 0/I, one early-stage primary peritoneal cancer, and three stage I or II ovarian cancers. Six additional breast cancers were detected by physical examination between radiographic screening intervals; four of these six tumors were stage I. No stage III or stage IV malignancies were detected after genetic testing. Conclusion: This study provides prospective evidence that genetic counseling and testing increased surveillance and led to risk-reducing operations, which resulted in diagnosis of early-stage tumors in patients with BRCA1 and BRCA2 mutations. (C) 2002 by American Society of Clinical Oncology.
引用
收藏
页码:1260 / 1268
页数:9
相关论文
共 50 条
  • [31] Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers
    Roger L. Milne
    Ana Osorio
    Teresa Ramón y Cajal
    Montserrat Baiget
    Adriana Lasa
    Eduardo Diaz-Rubio
    Miguel de la Hoya
    Trinidad Caldés
    Alex Teulé
    Conxi Lázaro
    Ignacio Blanco
    Judith Balmaña
    Gessamí Sánchez-Ollé
    Ana Vega
    Ana Blanco
    Isabel Chirivella
    Eva Esteban Cardeñosa
    Mercedes Durán
    Eladio Velasco
    Eduardo Martínez de Dueñas
    María-Isabel Tejada
    María-Dolores Miramar
    María-Teresa Calvo
    Carmen Guillén-Ponce
    Raquel Salazar
    Carlos San Román
    Miguel Urioste
    Javier Benítez
    Breast Cancer Research and Treatment, 2010, 119 : 221 - 232
  • [32] Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening
    Paluch-Shimon, S.
    Cardoso, F.
    Sessa, C.
    Balmana, J.
    Cardoso, M. J.
    Gilbert, F.
    Senkus, E.
    ANNALS OF ONCOLOGY, 2016, 27 : v103 - v110
  • [33] No sib pair concordance for breast or ovarian cancer in BRCA1 mutation carriers
    Moller, Pal
    Maehle, Lovise
    Clark, Neal
    Apold, Jaran
    HEREDITARY CANCER IN CLINICAL PRACTICE, 2007, 5 (02) : 67 - 71
  • [34] THE FREQUENCY AND OUTCOME OF BREAST CANCER RISK-REDUCING SURGERY IN FINNISH BRCA1 AND BRCA2 MUTATION CARRIERS
    Koskenvuo, L.
    Svarvar, C.
    Suominen, S.
    Aittomaki, K.
    Jahkola, T.
    SCANDINAVIAN JOURNAL OF SURGERY, 2014, 103 (01) : 34 - 40
  • [35] No Sib Pair Concordance for Breast or Ovarian Cancer in BRCA1 Mutation Carriers
    Pål Møller
    Lovise Mæhle
    Neal Clark
    Jaran Apold
    Hereditary Cancer in Clinical Practice, 5
  • [36] Breast Cancer Screening in BRCA Mutation Carriers: Necessity of a Relevant Update of Mammographic Modalities
    Colin, Catherine
    Doutriaux-Dumoulin, Isabelle
    RADIOLOGY, 2019, 293 (02) : 480 - 480
  • [37] IMPACT OF PREGNANCY ON THE RISK OF BREAST AND OVARIAN CANCER IN BRCA1 AND BRCA2 MUTATION CARRIERS
    Russo, M.
    Corvetto, E.
    Fais, M.
    Candotti, G.
    Locati, V.
    Proto, A.
    Angioni, S.
    Carcassi, C.
    Mais, V.
    Peiretti, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A391 - A391
  • [38] Breast cancer in BRCA mutation carriers: medical treatment
    Milani, Andrea
    Geuna, Elena
    Zucchini, Giorgia
    Aversa, Caterina
    Martinello, Rossella
    Montemurro, Filippo
    MINERVA GINECOLOGICA, 2016, 68 (05): : 557 - 565
  • [39] Costs of breast cancer surveillance in BRCA mutation carriers
    Kamm, Y. J. L.
    Boetes, C.
    Adang, E. M. M.
    Bult, P.
    Bonenkamp, H. J.
    Hoogerbrugge, N.
    EJC SUPPLEMENTS, 2008, 6 (07): : 94 - 95
  • [40] Ovarian Cancer Risk-Reduction and Screening in BRCA1/2 Mutation Carriers
    Disilvestro, Jessica B.
    Haddad, Jessica
    Robison, Katina
    Beffa, Lindsey
    Laprise, Jessica
    Scalia-Wilbur, Jennifer
    Raker, Christina
    Clark, Melissa A.
    Lokich, Elizabeth
    Hofstatter, Erin
    Dalela, Disha
    Brown, Amy
    Bradford, Leslie
    Toland, Maris
    Stuckey, Ashley
    JOURNAL OF WOMENS HEALTH, 2024, 33 (05) : 624 - 628